All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus
It is very uncertain whether levofloxacin changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with standard treatment (very low certainty).
1 finding from 1 review
Cure4 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events4 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Congestive heart failure · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Septic embolism4 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for cardiac surgical interventions · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uncontrolled infection4 · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis
It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with ciprofloxacin (very low certainty).
1 finding from 1 review
Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis
It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with comparator fluoroquinolone (very low certainty).
1 finding from 1 review
Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis
2 findings from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in clinical efficacy ‐ cure or improvement at end of treatment compared with ciprofloxacin (low certainty).
2 findings from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with ciprofloxacin (moderate certainty).
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Change in FVC · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa
Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).
1 finding from 1 review
Quality of life: change from baseline in CFQ‐R · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Survival · adults and children aged over 12 with CF and P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review